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Up-regulation of the folding machinery of the heat-shock protein
90 (Hsp90) chaperone protein is crucial for cancer progression. The
two Hsp90 isoforms (α and β) play different roles in response to
chemotherapy. To identify isoform-selective inhibitors of Hsp90
(α/β)/cochaperone p23 interactions, we developed a dual-luciferase
(Renilla and Fireﬂy) reporter system for high-throughput screening
(HTS) and monitoring the efﬁcacy of Hsp90 inhibitors in cell culture
and live mice. HTS of a 30,176 small-molecule chemical library in cell
culture identiﬁed a compound, N-(5-methylisoxazol-3-yl)-2-[4-(thi-
ophen-2-yl)-6-(triﬂuoromethyl)pyrimidin-2-ylthio]acetamide (CP9),
that binds to Hsp90(α/β) and displays characteristics of Hsp90
inhibitors, i.e., degradation of Hsp90 client proteins and inhibition
of cell proliferation, glucose metabolism, and thymidine kinase
activity, in multiple cancer cell lines. The efﬁcacy of CP9 in disrupt-
ing Hsp90(α/β)/p23 interactions and cell proliferation in tumor
xenografts was evaluated by non-invasive, repetitive Renilla lucif-
erase and Fireﬂy luciferase imaging, respectively. At 38 h post-
treatment (80 mg/kg × 3, i.p.), CP9 led to selective disruption of
Hsp90α/p23 as compared with Hsp90β/p23 interactions. Small-
animal PET/CT in the same cohort of mice showed that CP9 treat-
ment (43 h) led to a 40% decrease in 18F-ﬂuorodeoxyglucose up-
take in tumors relative to carrier control-treated mice. However,
CP9 did not lead to signiﬁcant degradation of Hsp90 client pro-
teins in tumors. We performed a structural activity relationship
study with 62 analogs of CP9 and identiﬁed A17 as the lead com-
pound that outperformed CP9 in inhibiting Hsp90(α/β)/p23 inter-
actions in cell culture. Our efforts demonstrated the power of
coupling of HTS with multimodality molecular imaging and led
to identiﬁcation of Hsp90 inhibitors.
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All proteins must be properly folded to perform their biologicalfunctions. In mammalian cells, the heat shock protein 90
(Hsp90) chaperone system plays a key role (1, 2). The most im-
portant interactions within the Hsp90 chaperone system are be-
tween Hsp90 isoforms (α and β) and cochaperone p23, which
occur only when Hsp90 is bound to ATP. These interactions are
crucial for maturation of Hsp90/client protein complexes and
the release of folded proteins (1, 2). Overexpression of Hsp90 in
human cancer cells correlates with poor prognosis (3, 4). Small-
molecule Hsp90 inhibitors with antitumor effects have been de-
veloped by targeting the ATP-binding pocket of Hsp90 (1, 5, 6).
They have higher binding afﬁnities to Hsp90 in cancer cells than
in normal cells (7) and competitively block ATP binding to Hsp90
and subsequent binding of p23. The prevention of proper protein
folding leads to proteasome-mediated degradation of Hsp90 client
proteins and inhibition of signaling pathways and growth arrest.
Geldanamycin-based Hsp90 inhibitors (8), purine scaffold– (9–
16), pyrazole scaffold– (17), and radicicol-based Hsp90 inhibitors
(18, 19), and other compounds are currently in preclinical and/or
phase I/II clinical trials (20–22). Despite the diversity of Hsp90
inhibitors reported, inhibitors with better clinical therapeutic
efﬁcacy and reduced toxicity are needed. Until now, methods
for identifying of Hsp90 inhibitors have been limited to in vitro
analyses (13, 23, 24) and phenotypic assays that examine the
downstream effects of the Hsp90 inhibition (9, 14, 15, 18). Small-
animal PET (25, 26), MRI (27), and ultrasound (28) have been
used to monitor the efﬁcacy of Hsp90 inhibitors in mice. How-
ever, it was not possible to decipher the contribution of each
Hsp90 isoform (α and β) in determining sensitivity to Hsp90
inhibitors, because both isoforms are expressed in cancer cells
but play different roles in response to chemotherapy (29).
We previously monitored the efﬁcacy of different Hsp90 in-
hibitors in disrupting isoform-speciﬁc interactions between Hsp90
(α/β) and p23 in intact cells in cell culture and in live mice using
a genetically encoded split Renilla luciferase (RL) complemen-
tation system (Fig. 1A) (30). This system is useful for identifying
Hsp90 inhibitors because (i) the potency of the Hsp90 inhibitors
in disrupting signals from Hsp90(α/β)/p23 interactions correlates
with their binding afﬁnities for cellular Hsp90; (ii) the inter-
action of each Hsp90 isoform (α or β) with p23 can be monitored
individually; (iii) RL does not require ATP for its activity and
thus facilitates the screening of inhibitors that target the ATP-
binding pocket of Hsp90; (iv) the same reporter cells can be used
for high-throughput screening (HTS) in cell culture followed by
dynamic monitoring of Hsp90(α/β)/p23 interactions in response
to lead compounds in living mice; and (v) the split RL comple-
mentation system in combination with other clinical imaging
modalities such as PET allows monitoring of the downstream
effects of Hsp90 inhibitors.
To accelerate the development of small-molecule Hps90
inhibitors, we incorporated multimodality molecular imaging
into HTS of an uncharacterized chemical library. We suc-
cessfully identiﬁed and monitored the efﬁcacy of a class of
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2-{[6-(triﬂuoromethyl)pyrimidin-2-yl]thio}acetamide-based Hsp90
inhibitors through molecular imaging of Hsp90(α/β)/p23 inter-
actions in living mice.
Results
HTS of Modulators of Hsp90(α/β)/p23 Interactions in Cell Culture. The
initial assay development was performed using the Library of
Pharmacologically Active Compounds (LOPAC) (31) with
293T human kidney cancer cells expressing the Hsp90α/p23 or
Hsp90β/p23 split RL reporters (30). Baseline bioluminescence
imaging (BLI) signals were determined before the addition of
LOPAC compounds. The known Hsp90 inhibitor PU-H71 (11)
was used a positive control. Twenty compounds were identiﬁed
with greater than 50% inhibition of BLI signals relative to carrier
control-treated cells at 24 h (Fig. 1B). Our initial screen demon-
strated that our assay conditions were optimal for discovery of
isoform-selective Hsp90(α/β)/p23 modulators in intact cells.
We proceeded to identify Hsp90 inhibitors using a commer-
cially available small-molecule chemical compound library with
30,176 compounds (8.3 μM each) with unknown targets and
molecular mechanisms (Fig. 1C). IC50 values were determined
for the 317 compounds that led to greater than 45% inhibition of
BLI signals relative to carrier control-treated cells. Inhibition of
cell proliferation at 20 μMwas determined, and toxic compounds
were eliminated. The IC50 values for inhibition of BLI signals
and cell proliferation by the top 19 compounds with the lowest
IC50 values for inhibition of Hsp90α/p23 interactions are shown
in Table 1, and their structures are given in Table S1. To de-
termine if any of the top compounds are nonspeciﬁc RL inhib-
itors, 293T cells stably expressing full-length RL were treated
with the compounds for different periods of time at levels 10-fold
higher than their respective IC50 for inhibition of Hsp90α/p23
interactions (Fig. 2A). Compounds that led to greater than 20%
inhibition of RL signals relative to carrier control-treated cells
were eliminated (Fig. S1).
Efﬁcacy of Lead Compounds in Inhibiting Hsp90 Chaperone Activities.
Hsp90 inhibitors lead to degradation of Hsp90 client proteins in
cancer cells (20, 32, 33). We initially focused on the two com-
pounds with the greatest inhibition of Hsp90α/p23 BLI signals,
CP1 and CP18, and on CP9, N-(5-methylisoxazol-3-yl)-2-[4-(thio-
phen-2-yl)-6-(triﬂuoromethyl)pyrimidin-2-ylthio]acetamide, which
was more selective for inhibition of Hsp90α/p23 BLI signals than
for inhibition of Hsp90β/p23 interactions (Table 1 and Fig. 2 B–D).
To determine if these compounds led to degradation of Hsp90
client proteins, 293T cells were treated with CP1, CP9, and
CP18, and the expression of phosphorylated Akt relative to total
Akt (pAkt/total Akt) and Raf-1 were determined by Western
blotting (Fig. 3A). Cells treated with PU-H71 served as a positive
control. CP1 did not decrease the levels of any of the three
Hsp90 client proteins signiﬁcantly; CP9 was more effective than
CP18 in degrading the pAkt, total Akt, and Raf-1 (Fig. 3A). PU-
H71 decreased levels of Raf-1, pAkt, and total Akt, as expected.
The disruption of endogenous Hsp90(α/β)/p23 interactions
by CP9 and CP18 was conﬁrmed by coimmunoprecipitation
(Fig. 3B). Based on our results, we focused our efforts on fur-
ther characterization of CP9 because of its efﬁcacy as an
Hsp90 inhibitor.
CP9 led to various levels of degradation of pAkt/total Akt and
Raf-1 in multiple cancer cell lines, including lung (1975), liver
(HUH-7), and breast (BT474) cancer cells, but had no effect on
the expression of the Hsp90 client proteins in normal mouse
embryonic ﬁbroblasts (MEFs) (Fig. S2A). To conﬁrm the direct
Fig. 1. HTS of Hsp90 inhibitors using the split RL complementation system
and evaluation of lead compounds by BLI. (A) The biological event that we
are monitoring (i.e., disruption of Hsp90/p23 interactions by Hsp90 inhib-
itors) is shown on the left. The schematic diagram for monitoring Hsp90/p23
interaction using the split RL complementation system is shown on the right.
The two interacting proteins, p23 and Hsp90, are fused to the inactive N-RL
and C-RL portions of RL through a peptide linker (Upper). In the presence of
ATP, interactions between p23 and Hsp90 bring N-RL and C-RL into close
proximity and lead to complementation of RL enzyme activity and the
production of light in the presence of the substrate coelenterazine. (Lower)
Binding of Hsp90 inhibitors (I) to Hsp90-CRL leads to a conformation change
and prevents ATP from binding, thus diminishing the interaction between
N-RL–p23 and Hsp90–C-RL and complementation of RL activity and reduced
light output. The effect of Hsp90 inhibitors on cell proliferation is monitored
by FL imaging upon introduction of the EGFP-FL fusion reporter. (B) HTS
using the 1,280-compound LOPAC for assay standardization. 293T cells stably
expressing the Hsp90α/p23 (solid bars) or Hsp90β/p23 (striped bars) split RL
reporter constructs were plated in 384-well white plates for 24 h. Baseline RL
signals were determined by a luminescence reader upon the addition of
the RL substrate EnduRen. Each compound in the LOPAC library (20 μM) or
carrier (control) then was added to a well, and RL signals at 24 h after
treatment were normalized to those of time 0 h and carrier control-treated.
The experiment was repeated twice. The percent of inhibition of RL activity
by the top 20 compounds is shown as mean ± SEM. (C) Flow diagram for HTS
of a 30,000 small-molecule compound library. Initial screening was per-
formed as in A, but only one well was used for each compound at 8.3 μM.
IC50 values for the compounds that resulted in >45% inhibition of Hsp90α/
p23 or Hsp90β/p23 interactions were determined by an eight-point dose–
response experiment (0.3–20 μM) (Table 1). Toxic compounds were elimi-
nated. Numbers within parentheses denote the number of compounds at
each stage during the screening.
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binding of CP9 to Hsp90(α/β), an in vitro competitive binding
assay was performed using puriﬁed Hsp90α/β and the radiolabeled
Hsp90 inhibitor [3H]17-allylamino-17-demethoxygeldanamycin
(3H-17-AAG). Hsp90 proteins were prebound with CP9 or cold
17-AAG as a control before incubation with 3H-17-AAG. Un-
bound 3H-17-AAG was removed, and the amount of 3H-17-AAG
bound to the Hsp90 proteins was determined. If CP9 binds to
Hsp90 (either in the same N-terminal ATP pocket or in other
portions of Hsp90 that are involved in binding 17-AAG), that
binding will reduce the amount of 3H-17-AAG bound to Hsp90.
Fig. 3C shows that CP9 reduced the binding of 3H-17-AAG to
puriﬁed Hsp90α by about 50% (P < 0.05) but did not affect the
binding to Hsp90β signiﬁcantly (P > 0.05). To conﬁrm cellular
Hsp90 as the target of CP9, we performed uptake studies in
HT29 cells using 3H-17-AAG. PU-H71 was used as a positive
control. CP9 led to a dose-dependent decrease in the uptake of
3H-17-AAG, with a maximum reduction of 30% relative to
carrier control-treated cells (P < 0.05) (Fig. 3D).
CP9 Inhibits Cell Proliferation, Glucose Metabolism, and Mammalian
Thymidine Kinase Activities in Multiple Cancer Cell Lines. To de-
termine if CP9 also inhibits cell proliferation, 2008 ovarian
cancer cells, 293T cells, U87-MG glioblastoma cells, and 1975
cells were treated with different concentrations of CP9, and cell
proliferation was monitored. CP9 was more effective than PU-
H71 and 17-AAG in inhibiting proliferation of U87-MG and
1975 cells but not of 293T and 2008 cells (Fig. 4A). Because CP9
led to a decrease in pAkt (Fig. 3A and Fig. S2A), we expected it
to inhibit glucose metabolism (34, 35), as monitored by cell-up-
take studies with [3H]ﬂuorodeoxyglucose (3H-FDG) (Fig. 4B)
(36). PU-H71 was used as a positive control. To determine the
speciﬁcity of CP9 in inhibiting glucose metabolism, normal MEF
cells were used as a control. CP9 decreased 3H-FDG uptake in
the cancer cells without signiﬁcantly affecting uptake in MEFs.
Likewise, CP9 inhibits uptake of [3H]3-ﬂuorodeoxy-thymidine
(3H-FLT) (a surrogate for thymidine kinase activity in mammalian
cells) in cancer cell lines but not in normal MEFs (Fig. S2B).
Collectively, our data show that CP9 binds to Hsp90 and leads
speciﬁcally to degradation of Hsp90 client proteins and in-
hibition of glucose metabolism, thymidine kinase activity, and
cell proliferation in cancer cells.
Noninvasive Monitoring of Disruption of Hsp90(α/β)/p23 Interactions
in Live Mice by CP9. To monitor the inhibition of Hsp90(α/β)/p23
interactions by CP9 in live mice by BLI, we introduced a second
reporter, FL-EGFP, into the 293T cells stably expressing Hsp90
(α/β)/p23 split RL reporters (hereafter, 293T(α/β)-FG cells). We
chose FL imaging because of its high sensitivity and the ease of
sequentially performing FL and RL imaging (37, 38). Baseline
RL and FL signals in each implanted tumor were determined.
Table 1. Effect of the lead compounds CP1–CP19 on inhibition
of Hsp90α/p23 and Hsp90β/p23 interactions and cell
proliferation
Compound
IC50 (Hsp90α/p23)
(μM)*
IC50 (Hsp90β/p23)
(μM)†
% inhibition cell
proliferation
(20 μM)‡
CP1 0.2 0.5 44
CP2 0.8 2.4 45
CP3 1.2 1.6 33
CP4 1.4 1.7 46
CP5 1.4 3.1 35
CP6 1.8 2.8 43
CP7 1.9 2.9 45
CP8 2.7 6.0 32
CP9 3.2 15.3 29
CP10 1.2 2.4 11
CP11 1.4 2.3 10
CP12 1.4 2.4 21
CP13 2.1 3.3 27
CP14 2.1 8.1 10
CP15 2.3 5.7 27
CP16 2.5 4.0 2
CP17 3.9 17.5 13
CP18 0.07 0.04 55
CP19 0.3 0.8 50
*IC50 was deﬁned as the concentration of the compound required to inhibit
bioluminescence signals by 50%, relative to carrier control-treated 293T cells
stably expressing Hsp90α/p23 split RL reporters.
†IC50 was deﬁned as the concentration of the compound required to inhibit
bioluminescence signals by 50%, relative to carrier control-treated 293T cells
stably expressing Hsp90α/p23 split RL reporters.
‡% Inhibition of 293T cells stably expressing Hsp90α/p23 split RL reporters by
each compound at 20 μM was determined by Cell Titer-Blue assay as de-
scribed in Materials and Methods.
Fig. 2. Elimination of nonspeciﬁc RL inhibitors and
determination of the efﬁcacy of lead compounds
from HTS in disruption of Hsp90(α/β)/p23 inter-
actions. (A) Elimination of nonspeciﬁc RL inhibitors
and validation of the lead compounds from HTS.
The top 19 compounds with the lowest IC50 values
for inhibition of Hsp90α/p23 interactions from Fig. 1A
were tested in cell culture in quadruplicate wells
to eliminate compounds that nonspeciﬁcally inhibit
RL activities. 293T cells stably expressing full-length
RL (293T-RL) were treated with carrier (control) (Rows
D–H, columns 9–12) or 10-fold higher concentrations
of the compounds (CP1–19) at their respective IC50
values for inhibition of Hsp90α/p23 interactions. RL
activities in intact 293T-RL cells were determined by
BLI at different time points posttreatment upon the
addition of EnduRen. (B–D) (Left) Dose-dependent
decrease in bioluminescence signals in 293T cells
stably expressing Hsp90α/p23 and Hsp90β/p23 split
RL reporters treated with CP1 (B), CP9 (C), or CP18
(D) at the indicated doses for 24 h. (Right) Bio-
luminescence signals were quantiﬁed and normalized
for cell number and signals of carrier control-treated
cells. Results are expressed as mean ± SEM.
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Based on our experience with Hsp90 inhibitors (30), we initially
tested CP9 (80 mg/kg) in mice (n = 5) by i.p. injection, with four
doses delivered immediately after and 16, 24, and 49 h after
baseline imaging (Fig. 5A). An equal volume of DMSO was
injected into the carrier control-treated group (n = 5) (Fig. 5B).
Mice treated with 75 mg/kg PU-H71 (n = 2) served as positive
controls. Mice were reimaged for Hsp90(α/β)/p23 interactions
and cell proliferation via RL (Fig. 5B, Left) and FL (Fig. 5B,
Right) imaging at the time points indicated. To account for the
effect of cell number on Hsp90(α/β)/p23 interactions, RL signals
were normalized to FL signals for each tumor at each time point,
before normalization to signal at time 0 h.
CP9 treatment led to the inhibition of RL signals in tumors
bearing Hsp90α/p23 (left ﬂank) and Hsp90β/p23 (right ﬂank)
xenografts, relative to time 0 h (Fig. 5A). Normalization of RL
signals for cell number shows that CP9 inhibits Hsp90α/p23
interactions in tumor xenografts (P < 0.05 at 38 h vs. carrier
control-treated mice) (Fig. 5C). CP9 was less effective in inhib-
iting Hsp90β/p23 interactions (P > 0.05 at both time points vs.
carrier control-treated mice) (Fig. 5D). At 62 h after CP9
treatment, the RL/FL ratios in Hsp90(α/β)/p23 xenografts were
similar to those in carrier control-treated mice (P > 0.05). Our
data are consistent with selectivity of CP9 in binding to Hsp90α
and inhibiting Hsp90α/p23 BLI signals in cell culture, relative
to Hsp90β/p23.
CP9 Led to Inhibition of Glucose Metabolism in 293T Xenografts as
Shown by Small-Animal [18F]Fluorodeoxyglucose PET/CT Imaging.
[18F]Fluorodeoxyglucose (18F-FDG) PET/CT has been used
routinely for repetitive and noninvasive monitoring of chemo-
therapy responses in small animals and in humans (39, 40). Be-
cause CP9 inhibits glucose metabolism in cancer cells (Fig. 4B),
we monitored its effect in tumor xenografts by small-animal 18F-
FDG PET/CT, using the same cohort of mice used for BLI (Fig.
5). Baseline 18F-FDG uptake was determined before treatment
with carrier control or CP9 (80 mg/kg) (Fig. 6A). The 18F-FDG
uptake in each tumor site relative to the maximum percent
injected dose per gram (maximum %ID/g) was determined upon
normalization of injected dose (41). In carrier control-treated
mice, 18F-FDG uptake in 293T tumors expressing Hsp90(α/β)/p23
RL reporters (n = 8) increased by 37 ± 18% at 43 h (Fig. 6B). On
the other hand, 18F-FDG uptake in CP9-treated tumors (n = 10)
decreased by 16 ± 9% (P < 0.005 relative to carrier control-treated
mice). Therefore, CP9 inhibits glucose metabolism in tumor
xenografts in live mice. We also analyzed the 18F-FDG uptake in
the brains of mice using CT images to delineate boundaries.
Relative to day 0, the maximum %ID/g of 18F-FDG uptake was
114 ± 11% in mice treated with carrier and 99 ± 4% in mice
treated with CP9 (Fig. 6C). There was no statistical difference
between the two groups (P > 0.05). Furthermore, there were no
signiﬁcant decreases in weight in CP9-treated mice compared
with carrier control-treated mice at 43 h (P > 0.05). Thus, our
Fig. 3. Validation of the mechanisms of lead compounds as Hsp90 inhibitors. (A) Effect of lead compounds on expression of Hsp90 client proteins. 293T cells
stably expressing Hsp90(α/β)/p23 split reporters were treated with carrier (control) or CP1, CP9, or CP18 (5 μM) for 24 h. The known Hsp90 inhibitor PU-H71
(2 μM) was used as a positive control. The expression of Hsp90 client proteins (Raf-1, total Akt, and pAkt) was determined by Western blotting. α-Tubulin was
used a loading control. (B) The effects of CP1, CP9, and CP18 on disruption of Hsp90α/p23 and Hsp90β/p23 interactions were determined by co-immunopre-
cipitation using antibodies against p23 and probing with Hsp90α- and Hsp90β-speciﬁc antibodies. The blot was probed with antibodies against p23 to ensure
similar immunoprecipitation efﬁciency. Cells treated with 2 μM of PU-H71 served as a positive control. (C) Competitive in vitro binding of CP9 with 3H-17-AAG
to Hsp90(α/β). Puriﬁed Hsp90(α/β) was preincubated with CP9 (200 μM) or cold 17-AAG (50 μM) before incubation with 3H-17-AAG. The reaction complexes then
were eluted through a desalting column to remove any unbound 3H-17-AAG before scintillation counting to determine the amount of 3H-17-AAG bound to
Hsp90(α/β). Columns incubated with 3H-17-AAG alone served as negative controls. Results are expressed as means of triplicates ± SEM. *P < 7.7 × 10−5 vs. Hsp90α +
3H-17AAG. (D) Inhibition of 3H-17-AAG uptake by CP9 in HT29 cells. HT29 cells were preincubated with different concentrations of CP9 along with 3H-17-AAG
(0.5 μM) for 1 h followed by 1 h of washout of unbound 3H-17-AAG in fresh Hank’s Balanced Salt Solution (HBSS). The amount of 3H-17-AAG incorporated
intracellularly was determined by scintillation counting of cell lysates, followed by normalization for protein content and to carrier control-treated cells. Cells
incubated with 5 μM of PU-H71 served as a positive control. Results are expressed as means of triplicates ± SEM. *P < 0.05 vs. carrier control-treated cells.
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current data do not indicate that CP9 poses signiﬁcant toxicity
in mice.
Ex Vivo Analyses of the Efﬁcacy of CP9 in Degrading Hsp90 Client
Proteins. To determine if the inhibition of Hsp90(α/β)/p23 in-
teractions also leads to degradation of Hsp90 client proteins in
mice, tumors were excised after PET/CT imaging to analyze the
expression of pAkt/total Akt and Raf-1 in tumor lysates. Fig. 6D
shows that CP9 treatment did not lead to signiﬁcant degradation
of Hsp90 client proteins relative to carrier control-treated mice
(P > 0.05). This observation is consistent with our imaging results
at 62 h after CP9 treatment, which did not show any signiﬁcant
differences in Hsp90(α/β)/p23 interactions in CP9-treated and
carrier control-treated mice (Fig. 5 C and D).
Evaluation of Efﬁcacy of Structural Analogs of CP9 in Disrupting
Hsp90(α/β)/p23 Interactions and Degrading Hsp90 Client Proteins. In
attempt to improve the efﬁcacy of CP9, we performed a struc-
ture–activity relationship (SAR) study using 62 analogs of
CP9 with different modiﬁcations (Table S2). Their effects on
Hsp90(α/β)/p23 interactions and cell proliferation in stable 293T
(α/β)-FG cells were monitored by sequential RL (Fig. S3A) and
FL imaging. CP9, PU-H71, and 17-AAG were used as positive
controls. Compared with the parent compound CP9, the analogs
A14 and A17 led to similar inhibition of Hsp90α/p23 and Hsp90β/
p23 interactions (Fig. S3B, diamonds and squares, respectively).
Time– and dose–response curves were established for the top 13
analogs with the lowest IC50 values for inhibition of Hsp90α/p23
interactions (Fig. S4A).
When we compared derivatives of CP9 with different R3
substitutions (A1–16, A18–31, A35, A37, A39, A42–44, A46,
A47, A49, A51, A53, A55, A56, and A59–62), we found that an
aromatic moiety is required and that aliphatic substitution led to
diminished efﬁcacy in disrupting Hsp90(α/β)/p23 interactions. A
single small ortho substitution on the aromatic ring (as in A14
and A23) and methyl substitution in the meta position (A29 and
A61) were tolerated. In CP9 analogs with various R1 substitutions
(A17, A45, A48, A50, and A57), a ﬁve-member aromatic ring
seems to be required for binding; analogs containing phenyl rings
with various substitutions in the R1 position exhibited lower activity.
Only replacement of the thiophen moiety in CP9 by a furanyl
substitution (A17) was tolerated and led to higher potency.
Methyl substitution in the R2 position was advantageous: A34 and
A50 tend to have higher afﬁnity than A40 and A45, respectively.
The best analogue with the lowest IC50 for inhibition of
Hsp90α/p23 interactions was A17, which reduced the IC50 for the
inhibition of Hsp90α/p23 signals by threefold compared with
CP9 (0.15 vs. 0.45 μM) and which had a twofold-lower IC50 for
growth inhibition (Fig. 7A). To determine if the reduction in IC50
for Hsp90(α/β)/p23 interactions makes A17 a more efﬁcacious
inhibitor of Hsp90, 293T-FG cells were treated with CP9 and
A17. PU-H71 and 17-AAG were used as positive controls. A17
was more effective than CP9 in degrading pAkt/total Akt and
Raf-1 (Fig, S4B). Because CP9 and its analogs inhibit Hsp90
(α/β)/p23 interactions and lead to the degradation of Hsp90
client proteins, we have identiﬁed a class of Hsp90 inhibitors.
Because A17 has a lower partition coefﬁcient than CP9 (2.8 vs.
4.1), it may be more hydrophilic with less nonspeciﬁc binding of
serum proteins and better bioavailability in tumors (42). Con-
trary to cell-culture results, treatment with A17 did not lead to
signiﬁcant decreases in Hsp90(α/β)/p23 interactions in tumor
xenografts as compared with carrier control-treated mice using the
same dosing regimen (P > 0.05 vs. carrier control-treated mice)
(Fig. 7 B and C), perhaps because the bioavailability of A17 led to
insufﬁcient intratumoral concentrations for inhibiting Hsp90
(α/β)/p23 interactions and subsequently degrading Hsp90 cli-
ent proteins (Fig. 7D). Despite this outcome, we have estab-
lished a SAR study platform that allows rapid screening and
evaluation of more potent CP9 analogs, ﬁrst in cell culture and
subsequently in live mice.
Discussion
In the current work we successfully coupled multimodality
molecular imaging into HTS and discovered a class of 2-{[6-
(triﬂuoromethyl)pyrimidin-2-yl]thio}acetamide–based Hsp90
inhibitors. We used a dual RL/FL reporter system for monitoring
isoform-selective Hsp90(α/β)/p23 interactions and cell proliferation
in intact cells. Among the three lead compounds, we focused on
CP9 rather than CP1 and CP18 because it was more potent in
degrading Hsp90 client proteins including Raf-1, pAkt, and total
Akt (Fig. 2A) as well as in disrupting Hsp90(α/β)/p23 interactions
(Fig. 2B). Furthermore, CP9 exhibits selectivity in binding to pu-
riﬁed Hsp90α and inhibiting Hsp90α/p23 interactions. Therefore
we focused our efforts on characterizing CP9 as an Hsp90 in-
hibitor. We also noninvasively and repetitively monitored the
inhibitory effects of CP9 on Hsp90(α/β)/p23 interactions and
glucose metabolism in tumor xenografts. Finally, we performed
SAR studies and identiﬁed a more potent analog of CP9, A17.
Fig. 4. Effect of CP9 on glucose metabolism and cell proliferation in dif-
ferent cancer cell lines. (A) The effect of CP9 on cell proliferation was de-
termined by Alamar Blue assay. The indicated cancer cell lines were treated
with different concentrations of CP9 for 24 h before incubation with Alamar
Blue for 4 h. The Hsp90 inhibitors PU-H71 and 17-AAG were used as positive
controls. Emission at 570 nm in CP9-treated cells was normalized to that of
carrier control-treated cells. Results are expressed as normalized cell pro-
liferation ± SEM. (B) The effect of CP9 on glucose metabolism was de-
termined in 1975 (lung cancer), 2008 (ovarian cancer), and HT29 (colon
cancer) cells by 3H-FDG–uptake studies 24 h after treatment. Normal MEFs
were used as a control. Results are expressed as mean counts·microgram
protein−1·initial dose−1 ± SEM. *P < 0.05 vs. carrier control-treated cells.
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CP9 as a 2-{[6-(Triﬂuoromethyl)Pyrimidin-2-yl]Thio}Acetamide–Based
Hsp90 Inhibitor. CP9 competes with 3H-17-AAG for binding to
puriﬁed Hsp90(α/β), reduces uptake of 3H-17-AAG in intact
HT29 cancer cells, and disrupts Hsp90(α/β)/p23 interactions in
intact 293T cells (Fig. 3). Our data indicated that CP9 binds
to Hsp90. CP9 treatment leads to the degradation of Hsp90
client proteins and inhibition of glucose metabolism, mammalian
thymidine kinase, and cell proliferation in multiple cancer cell
lines. The inhibition of Hsp90 chaperone activities is speciﬁc for
cancer cells, because CP9 had no effect on normal MEFs. The
small chemical library that contains CP9 was used by other
investigators in bioassays that were not speciﬁcally designed for
monitoring Hsp90(α/β)/p23 interactions. Targets that were re-
ported in PubChem (http://pubchem.ncbi.nlm.nih.gov/) to be
affected by CP9 include β-adrenergic receptor kinase 1, poly-
pyrimidine tract-binding protein 1α, and 5-hydroxytryptamine
receptor 1E. It has been reported in PubChem that CP9 inhibits
proliferation, protein assembly, and kinase activities in different
cancer cell lines. Because Hsp90 is involved in the regulation of
kinases, receptors, and protein binding/folding, our data are
consistent with others who have reported the downstream effects
of CP9 (43).
Both Hsp90 isoforms (α and β) are expressed in cancer cells,
but Hsp90β is constitutively expressed, whereas the expression of
Hsp90α is highly inducible during stress and drug treatment (29,
44). Using our genetically encoded split Renilla reporter system,
we were able to decipher the individual contributions of each
isoform in determining the sensitivity of Hsp90 inhibitors. It was
reported that the transcription of MDR1 is regulated by HSF-1,
which in turn is regulated by Hsp90α (45). To determine the
biological signiﬁcance of CP9 selectivity in inhibiting Hsp90α/p23
interactions, we used V79 lung cancer cells and V79/ADR cells
that overexpress multidrug-resistant protein and are insensitive
to growth inhibition by doxorubicin (DOX). V79 and V79/ADR
cells were treated with DOX alone or in the presence of CP9. In
V79 cells that do not express MDR-1, the sensitivity to DOX was
not affected by CP9 (Fig. 8A). On the other hand, the addition of
CP9 sensitized V79/ADR cells to DOX, as shown by the de-
crease in cell proliferation relative to treatment with DOX alone
(Fig. 8B). Similar results were observed with the known Hsp90
inhibitor PU-H71 (Fig. 8C), which is more selective for disrup-
tion of Hsp90α/p23 interactions (30). Our results also are con-
sistent with the observation that derivatives of Hsp90 inhibitor
peptides sensitize cancer cells with overexpression of MDR to
epirubicin (a class of anthracyclines that includes DOX) (46).
Further studies will be required to determine the mechanisms of
CP9 in reversal of MDR-1–mediated DOX resistance.
We noninvasively and repetitively monitored the inhibitory
effects of CP9 in tumor xenografts in live mice by multimodality
molecular imaging. BLI shows that CP9 selectively inhibits
Hsp90α/p23 interactions relative to Hsp90β/p23 interactions
(Fig. 5), and 18F-FDG PET/CT in the same cohort shows that
CP9 inhibits glucose metabolism (Fig. 6). The selective inhibition
of Hsp90α/p23 interactions and reduction in glucose metabolism
in mice were consistent with the cell-culture results. However,
CP9 did not decrease the expression of the Hsp90 client proteins
signiﬁcantly. Our results illustrate the challenges of transitioning
Fig. 5. BLI of the efﬁcacy of CP9 in disruption of Hsp90(α/β)/p23 interactions and cell proliferation. To monitor the disruption of Hsp90(α/β)/p23 interactions
by CP9 noninvasively and repetitively in living subjects, nude mice bearing 293T xenografts expressing the Hsp90(α/β)/p23 split RL reporters and EGFP-FL
reporters [293T(α/β)/p23-FG] were used. Mice ﬁrst were imaged for baseline RL signals from Hsp90α/p23 interactions (tumors on left ﬂank) and Hsp90β/p23
interactions (tumors on right ﬂank) using a cooled CCD camera upon i.v. injection of coelenterazine. The RL signals were allowed to decay for 30 min to allow
clearance of coelenterazine, before the baseline cell proliferation was monitored by FL imaging upon i.v. injection of D-luciferin. Mice (n = 5 per group) then
were randomized based on FL signals for treatment with CP9 (four doses of 80 mg/kg in DMSO) or carrier (DMSO; control) by i.p. injection. Mice (n = 2) treated
with PU-H71 (75 mg/kg) served as positive controls. RL and FL signals were determined at different time points after treatment upon reinjection of coe-
lenterazine and D-luciferin. (A and B) Representative RL (Left) and FL (Right) images frommice treated with CP9 (A) or carrier (control) (B). (C) RL and FL signals
for each mouse were quantitated by drawing the same size ROI on each site at all time points. Maximum radiance (photons·s−1·cm2−1·steridian−1) from RL
signals was normalized to that of FL signals at each site and at each time point to account for the effect of CP9 on cell proliferation. The RL/FL ratios then were
normalized to that of time 0 h to monitor the individual change in Hsp90(α/β)/p23 interactions in each mouse over time. Results are expressed as mean ± SEM
for the control and treatment groups for Hsp90α/p23 (Upper) and Hsp90β/p23 (Lower) interactions.
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from cell culture to animal studies in which the efﬁcacy of lead
compounds is limited by their tumor bioavailability (47).
Uniﬁed System Accelerated Drug Discovery, Mechanism Validation,
and Lead Optimization in Living Subjects. In attempt to improve the
potency of CP9, SAR studies were performed on the 62 analogs
of CP9. The efﬁcacy in degrading Hsp90 client proteins corre-
sponds to the inhibition of BLI signals (Fig. S4). Furthermore,
the most potent analog, A17, was more effective than CP9 in
inhibiting Hsp90(α/β)/p23 interactions and degrading Hsp90
client proteins in cell culture (Fig. S4B) but not in live mice (Fig.
6D). Nevertheless, the class of compounds that we have identi-
ﬁed is distinct from PU-H71, which was used as a positive control
for our experiments. Our data conﬁrm the CP9 family as 2-
{[6-(triﬂuoromethyl)pyrimidin-2-yl]thio}acetamide–based Hsp90
inhibitors. However, further work in medicinal chemistry is
necessary to optimize our lead compound in terms of potency,
bioavailability, and other parameters important for therapeutic
efﬁcacy. Furthermore one could use some of the distinctive com-
ponents of the chemical structure of CP9 further to derivatize
chemically the compounds CP18 and CP19, which exhibited the
lowest IC50 values. Our strategy allows rapid evaluation of such
structural analogs using small quantities and will reduce the costs
of compound syntheses.
In summary, we have identiﬁed and validated a class of
Hsp90 inhibitors by coupling molecular imaging with HTS. Our
work-ﬂow allows rapid identiﬁcation of cell-permeable lead
compounds in cell culture, followed by monitoring of efﬁcacy
in live mice. This approach will accelerate signiﬁcantly the
development of the next generation of therapeutics aimed at
inhibiting speciﬁc chaperone–protein interactions.
Materials and Methods
Chemicals, Enzymes, and Reagents. Coelenterazine was purchased from
Nanolight Technology. Cell culture media, FBS, penicillin/streptomycin (P/S),
and 4–12% (wt/vol) gradient SDS/PAGE gels were purchased from Invi-
trogen. Puromycin hydrochloride and 17-AAG were purchased from Inviv-
ogen. Purine-scaffold Hsp90 inhibitor PU-H71 (13, 14, 48) was dissolved as
7.65 mM PBS stock and stored at −20 °C. The slow-kinetic RL substrate
EnduRen (Promega) was dissolved in DMSO as 34 mg/mL stock and stored
at −20 °C. Doxorubicin hydrochloride was purchased from Sigma.
Cell Culture. All cell lines used in this study were purchased from American
Type Culture Collection and were cultured with their respective medium
supplemented with 10% FBS and 1% P/S. 293T HEK cancer cells stably ex-
pressing Hsp90(α/β)/p23 split RL reporters (30) were maintained in Eagle’s
Minimal Essential Medium medium and 1.5 μg/mL of puromycin. MCF-7
human breast adenocarcinoma cells and 2008 human ovarian cancer cells
were maintained in RMPI medium. U87MG human glioblastoma cells, SKBr3
human breast carcinoma cells, 1975 lung cancer cells, HUH-7 and 4–4 liver
cancer cells (received from Dean Felsher, Stanford University, Stanford, CA),
PC-3 human prostate cancer cells, and V79 and V79/ADR hamster lung cancer
cells (resistant to doxorubicin) were cultured with DMEM.
HTS of Small-Molecule Chemical Libraries Using 293T Cells Stably Expressing
Hsp90(α/β)/p23 Split RL Reporters. To identify Hsp90 inhibitors the LOPAC
from Sigma was used. HTS was performed at the Stanford High-Throughput
Bioscience Center. 293T HEK cells (8 × 103) from columns 1–22 (E & K Sci-
entiﬁc) expressing Hsp90α/p23 or Hsp90β/p23 split RL reporters were plated
in each well of the 384-well white-bottomed plate in 60 μL of medium using
the Wellmate matrix (Thermo Scientiﬁc) and were allowed to attach for
Fig. 6. CP9 led to inhibition of glucose metabolism in tumor xenografts by PET/CT imaging but did not lead to signiﬁcant degradation of Hsp90 client
proteins. (A) To determine the downstream effects of CP9 on glucose metabolism in 293T(α/β)/p23-FG xenografts, small-animal PET/CT imaging was performed
using 18F-FDG. To obtain anatomical information, mice were imaged using the CT module of the PET/CT machine before PET scanning. Baseline 18F-FDG
uptake was determined at time 0 h before treatment with four doses of CP9 (n = 5 per group) or carrier (control; n = 4 per group). Mice were reimaged at 43 h.
PET and maximum intensity projection of the PET/CT images of representative mice treated with CP9 (Left) or carrier (control) (Right) are shown. The dotted red
circles outline the locations of Hsp90α/p23 xenografts on the left ﬂanks and Hsp90β/p23 xenografts on the right ﬂanks. The color bar represents%ID/g for 18F-FDG
uptake in tumors in PET images. (B) Quantitation of the effect of CP9 on inhibition of glucose metabolism. The PET image of each mouse and each site at each
time point was reconstructed and quantiﬁed using the OSEM 2D algorithm. The increase in max%ID/g at 43 h relative to 0 h is shown here as average ± SEM. CP9
led to signiﬁcant decrease in glucose metabolism, compared with carrier control-treated mice (P < 0.005). (C) CP9 did not signiﬁcantly inhibit 18F-FDG uptake in
brain (P > 0.05 relative to carrier control-treatedmice). (D) Validation of the mechanism of CP9 as an Hsp90 inhibitor in live mice. After the last imaging time point,
tumors were excised from the mice, and the expression of Raf-1, pAkt, and total Akt was determined by Western blotting as in Fig. 3A. α-Tubulin was used as
a loading control. CP9 did not lead to a signiﬁcant decrease in the expression of Hsp90 client proteins, relative to carrier control-treated mice.
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24 h. Sixty microliters of medium (without cells) was added to columns 23
and 24 to control for background signals caused by substrate alone. Then
approximately 100 nL of each LOPAC compound (10 mM stock in DMSO) was
added to each well in columns 3–22 (ﬁnal concentration ∼17 μM) using
a PinTool (V&P Scientiﬁc) on a Sciclone ALH3000 (Caliper Sciences). Cells in
columns 1 and 2 that were not treated with the compounds were used to
determine the baseline signals from Hsp90(α/β)/p23 interactions.
Baseline-complemented RL activities were determined 90 min after the
addition of 20 μL of EnduRen (10 μM ﬁnal concentration) (Promega) using
the Analyst GT Multimode Reader (Molecular Devices), with an acquisition
time of 0.2 s per well. Cells were incubated with compounds for 24 h before
redetermination of complemented RL activities and were normalized to the
mean RL activities of untreated cells in columns 1 and 2. Another small-
molecule chemical library with 30,176 compounds (SPECS) also was used in
screening modulators of Hsp90(α/β)/p23 inhibitors (at 8.3 μM, one drug per
well for initial screening). For the dose–response conﬁrmation assay the
compounds were tested in duplicate in an eight-point (0.156–20 μM) dose–
response assay for RL activities for both Hps90(α)/p23 and Hps90(β)/p23
interactions. The effect of each compound on cell proliferation at 20 μMwas
determined using the Cell Titer-Blue assay (Promega) in duplicate wells.
Elimination of Nonspeciﬁc Compounds. To determine if the 19 lead hit com-
pounds were nonspeciﬁc inhibitors of RL activities, 3 × 104 293T cells stably
expressing full-length RL were plated in each 96-well black-walled plate for
24 h. They were treated for 4–24 h with different compounds at a 10-fold
higher concentration than their respective IC50 for inhibition of Hsp90α/p23
BLI signals. Carrier-treated (0.1% DMSO) cells were used as the positive
control. RL signals were determined using a cooled CCD camera upon the
addition of EnduRen (90 min, ﬁnal concentration of 10 μM) and were nor-
malized to that of carrier control-treated cells. Compounds that inhibited RL
signals by more than 20% were excluded from further analyses. Other toxic
and nonspeciﬁc compounds were eliminated based on database analyses
of previous screening assays performed at the Stanford High-Throughput
Bioscience Center.
Determination of Efﬁcacy of Lead Compounds in Disrupting Hsp90(α/β)/p23
Interactions. To determine the effect of lead compounds on disruption of
Hsp90(α/β)/p23 interactions in intact cells, 3.5 × 104 293T cells stably trans-
fected with split RL reporters (30) were plated in each well in the 96-well
black-walled plate (Costar, Corning) and were allowed to attach for 24 h
before treatment with different concentrations of the lead compounds for
24 h. Then 10 μg/mL of EnduRen (in 50 μL of cell-culture medium) was added
to each well for 1.5 h, and RL activities were determined. BLI signals were
normalized to that of the cell number for each well [determined by
AlamarBlue assay (Invitrogen)] before normalization to carrier control-
treated cells.
Western Blotting and Coimmunoprecipitation. To validate the mechanisms of
the lead compounds and their analogs for inhibiting Hsp90(α/β)/p23 inter-
actions, 293T cells stably expressing the Hsp90(α/β)/p23 split reporters were
treated with 5 μM of CP1, CP9, CP18, or carrier (control) for 24 h. Cells
treated with 2 μM of PU-H71 served as a positive control. Western blotting
of Hsp70, pAkt, and total Akt, and co-immunoprecipitation of Hsp90(α/β)/p23
interactions were performed as described previously (30). The expression of
Raf-1 was determined using rabbit polyclonal antibodies against Raf-1 (0.5
μg/mL) (Abcam).
3H-FDG and 3H-FLT Cell-Uptake Studies. To determine the downstream effects
of lead compounds on glucose metabolism, 1.5 × 105 293T, 1975, and 2008
cells and MEFs were plated in a 24-well plate for 24 h before treatment with
different concentrations of CP9 for 24 or 48 h and subsequent incubation
with 1 μCi of 3H-FDG in 500 μL of medium for 1 h at 37 °C, as described
previously (49). Cells treated with 2.5 μM of PU-H71 served as a positive
control. The total counts in each sample were normalized to that of the dose
added to each well and to the amount of protein and were expressed as
mean counts·dose−1·microgram protein−1 ± SEM. Likewise, the effect of CP9
on cell proliferation was determined using 1 μCi of 3H-FLT per well after 2 h
of incubation at 37 °C (50).
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Fig. 7. Efﬁcacy of lead CP9 analog A17 in cell culture and in live mice. (A) Effect of A17, CP9, and 17-AAG on proliferation of 293T cells. 293T cells were
treated with different concentrations of inhibitors in triplicate for 24 h before cell proliferation was determined by Alamar Blue assay. Emission signals were
normalized to those of carrier control-treated cells and are expressed as mean ± SEM. (B) Effect of A17 on Hsp90α/p23 interactions in mice bearing 293T-FG
xenografts. Mice were treated with four doses of A17 (80 mg/kg) after the establishment of baseline RL signals (Hsp90α/p23) and FL signals (cell proliferation)
and were reimaged at the indicated time points. The net effect of A17 on Hsp90α/p23 interactions was determined as in Fig. 5C. Relative to carrier control-
treated mice, A17 led to decreases in Hsp90α/p23 interactions at 43 h, but the differences were not statistically signiﬁcant (P > 0.05). (C) Effect of A17 on
Hsp90β/p23 interactions in mice bearing 293T-FG xenografts was determined as A. A17 did not lead to a signiﬁcant decrease in Hsp90β/p23 interactions
(P > 0.05 relative to carrier control-treated mice). (D) Ex vivo analyses of Hsp90 client proteins in excised tumors from B and C. The expression of pAkt, total
Akt, and Raf-1 was determined by Western blotting as in Fig. 6D, and α-tubulin was used a loading control. A17 did not lead to signiﬁcant decreases in Hsp90
client proteins (P > 0.05 relative to carrier control-treated mice).
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Puriﬁed Hsp90(α/β) Binding Assay. To verify the binding of CP9 to Hsp90α and
Hsp90β in vitro, a displacement assay using 3H-17-AAG was performed. One
microgram of puriﬁed Hsp90α or Hsp90β was incubated with different
concentrations of CP9 or DMSO carrier (control) in 50 μL of HBS-P+ binding
buffer (Biacore) for 1 h on ice on a shaking platform. 17-AAG (ﬁnal con-
centration of 200 μM) was used as a positive control. Duplicate samples were
used for each condition. One microliter of 3H-17-AAG (ﬁnal concentration of
0.5 μM) was added, and the mixture was incubated for another 30 min at
room temperature. Unbound 3H-17-AAG and inhibitors were removed
using the 7-kDa Zeba desalt column (Thermo Scientiﬁc). The amount of
3H-17-AAG that remained bound to Hsp90α or Hsp90β was determined by
scintillation counting.
Displacement of 3H-17-AAG Uptake by CP9 in HT29 Cells. To determine if CP9
binds to cellular Hsp90, an uptake study of 3H-17-AAG (Moravek Biochemicals)
was performed. HT29 cells (1 × 105 in 500 μL of medium) were plated in each
well of a 24-well plate and were allowed to attach for 24 h. Cells were in-
cubated with 0.5 μM 3H-17-AAG in the presence of 0.4–12.5 μM CP9 or carrier
(control) for 1 h at 37 °C. PU-H71 (5 μM) was used as a positive control.
This incubation was followed by two washes with 500 μL of PBS and 1 h of
washout in 500 μL Hank’s Balanced Salt Solution (HBSS) to remove unbound
3H-17-AAG. Cells were lysed on ice for 15 min in 300 μL of T-PER tissue ex-
traction buffer in the presence of protease and phosphatase inhibitors
(Thermo Scientiﬁc), and cell lysates were prepared for scintillation counting
and protein determination. The total counts in each sample were normalized
to that of the dose added to each well and to the amount of protein and are
expressed as mean counts·dose−1·microgram protein−1 ± SEM.
Optical CCD Imaging in Live Mice. Animal care and handling were performed
in accordance with Stanford University Animal Research Committee guide-
lines. Mice were gas anesthetized using isoﬂuorane (2% in 100% oxygen, 1
L/min) during all injection and imaging procedures and were kept at 37 °C.
Mice were imaged using a cooled CCD camera (IVIS 200; Caliper Life Scien-
ces). Tumor establishment and BLI of 293T cells stably expressing Hsp90
(α/β)/p23 split RL reporters and FL-EGFP in 7-wk-old female nude mice (nu/nu;
Charles River) were performed as described previously (30). Baseline RL
activity in the implanted tumors in live mice was determined by i.v. injection
of 30 μg coelenterazine (in 150 μL of 5% ethanol/95% PBS) and image
acquisitions of 3 min. After a 30-min wait for RL signals to decay, FL activities
were determined by i.v. injection of 163 μg of D-luciferin (Biosynth, Itasca, IL)
in 100 μL PBS with image acquisition of 10 sequences (15 s each) to obtain
the peak maximum radiance. One set of mice (n = 5 per group) was injected
i.p. with 80 mg/kg CP9 dissolved in 100% DMSO in a ﬁnal volume of 60 μL.
Another set of mice (n = 5) was treated with an equal volume of DMSO as
control. At different time points after treatment, follow-up RL and FL im-
aging was performed to monitor the effects of CP9 on complemented Hsp90
(α/β)/p23 interactions and cell proliferation. The maximum radiance of RL
was divided by that of FL signals at each time point, before normalization to
that of time 0 h for each individual mouse, and was expressed as average
radiance ± SEM for each treatment group.
Mice were euthanized after the last imaging time points, and tumors were
excised and homogenized in tissue extraction buffer in the presence of Halt
Complete protease and phosphatase inhibitors (all from Pierce). Protein
concentrations were determined by the Bio-Rad Protein DC assay. Expression
of pAkt/total Akt, Raf-1, and α-tubulin was determined by Western blotting
(30). Western blot images were quantitated using Image J (National Institutes
of Health) and were expressed as the ratio of target protein to α-tubulin for
each treatment group.
PET/CT Imaging of Glucose Metabolism in Live Mice. To determine the effects
of CP9 on glucose metabolism in 293T xenografts stably expressing Hsp90
(α/β)/p23 split RL reporters and FL-EGFP, baseline 18F-FDG uptake in each
tumor site for each mouse was determined by small-animal PET imaging
using the Inveon PET/CT scanner (Siemens). Mice were placed on a custom-
built four-mice holder ﬁrst for CT image acquisition (632 slices at 206 μm)
that was used both for photon attenuation correction and image coregis-
tration with PET image data for anatomical information. A static 5-min PET
scan then was performed for [18F]-FDG activity and was reconstructed using
the Ordered Subsets Expectation Maximization (OSEM) 2D algorithm (159 sli-
ces with 1.5-mm resolution). Region of interest (ROI) analysis was performed
using the Inveon Research Workspace software. The maximum %ID/g upon
normalization to injected dose was determined before and 43 h after CP9
treatment.
Data Analysis. Each experiment was repeated at least three times, and results
are expressed as mean ± SEM. Statistical differences were determined by
Student’s t test using P < 0.05 as the cutoff point. HTS data were analyzed
using Accelrys Assay Explorer (Accelrys Inc., San Diego, CA).
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Fig. 8. Inhibition of cell proliferation of DOX-resistant V79/ADR lung cancer
cells by CP9 and the Hsp90 inhibitor PU-H71 in cell culture. To determine if
CP9 can inhibit proliferation of DOX-resistant lung cancer cells, V79 lung
cancer cells and V69/ADR cells that are resistant to DOX were treated with
DOX (0.31–10 μM) in the presence or absence of CP9 (8 μM) for 24 h before
determination of cell number by Alamar Blue assay. (A) CP9 did not affect
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